Ex situ heart perfusion: A novel platform to test cardiovascular therapeutics in human hearts.

ABSTRACT:

Background

Explanted hearts from recipients undergoing cardiac transplantation may be utilized as a human model of cardiomyopathy. Ex-situ perfusion of hearts allows control of the physiological and biochemical conditions of perfusion. AZD8601 is a novel modRNA for VEGF-A that was shown to be safe in a Phase IIa clinical trial - the EPICCURE trial. This proof-of-concept study aimed to demonstrate the potential utility of testing novel therapies on explanted recipient hearts using ex situ machine perfusion.

Methods

In order to ascertain the expression of VEGF-A in a human model of cardiomyopathy, AZD8601 was injected at high- and low-dose into the mid-myocardium of the left ventricle of human hearts explanted at the time of cardiac transplantation and perfused o

SUBMITTER: Louca JO 

PROVIDER: S-EPMC12310391 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature